300463.SZ
Maccura Biotechnology Co.Ltd [300463.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
300463.SZ Stock Summary
Top 10 Correlated ETFs
300463.SZ
Top 10 Correlated Stocks
300463.SZ
In the News
300463.SZ Financial details
Company Rating
Buy
Market Cap
7.55B
Income
375.99M
Revenue
3.01B
Book val./share
10.34
Cash/share
1.93
Dividend
0.35
Dividend %
2.44%
Employees
3.02K
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
23.35
Forward P/E
-
PEG
-3.62
P/S
2.98
P/B
1.39
P/C
6.06
P/FCF
-25.11
Quick Ratio
2.71
Current Ratio
3.71
Debt / Equity
0.13
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.61
EPS next Y
-
EPS next Q
-
EPS this Y
-32.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
7.9%
Revenue last 5Y
6.09%
Revenue Q/Q
4.26%
EPS Q/Q
58.56%
-
-
-
-
SMA20
-9.9%
SMA50
-4.8%
SMA100
-22.52%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
6%
ROC
0.06%
Gross Margin
56%
Oper. Margin
15%
Profit Margin
13%
Payout
64%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.9-18.84
52W High
-35%
52W Low
+30%
RSI
37.57
Rel Volume
0.44
Avg Volume
5.75M
Volume
2.51M
Perf Week
-7.22%
Perf Month
-7.29%
Perf Quarter
-16.49%
Perf Half Y
-22.82%
-
-
-
-
Beta
0.378
-
-
Volatility
0.33%, 0.6%
Prev Close
-0.59%
Price
11.7
Change
-2.09%
300463.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.85 | 5.83 | 6.69 | 7.2 | 5.97 | |
| Net income per share | 0.8 | 0.95 | 1.43 | 1.73 | 1.17 | |
| Operating cash flow per share | 0.35 | 0.83 | 1.97 | 2.93 | 1.4 | |
| Free cash flow per share | -0.61 | -0.08 | 1.07 | 1.84 | -0.24 | |
| Cash per share | 0.77 | 0.79 | 0.95 | 1 | 2.07 | |
| Book value per share | 4.87 | 5.65 | 6.85 | 7.78 | 10.42 | |
| Tangible book value per share | 4.87 | 5.6 | 6.75 | 7.67 | 9.95 | |
| Share holders equity per share | 4.87 | 5.65 | 6.85 | 7.78 | 10.42 | |
| Interest debt per share | 2.24 | 2.84 | 2.51 | 2.13 | 1.22 | |
| Market cap | 7.74B | 14.92B | 25.82B | 16.13B | 10.45B | |
| Enterprise value | 8.49B | 15.98B | 26.52B | 16.61B | 10.56B | |
| P/E ratio | 17.39 | 28.41 | 32.52 | 16.87 | 14.76 | |
| Price to sales ratio | 2.88 | 4.63 | 6.97 | 4.05 | 2.9 | |
| POCF ratio | 39.91 | 32.47 | 23.6 | 9.98 | 12.39 | |
| PFCF ratio | -23.03 | -330.45 | 43.55 | 15.9 | -72.3 | |
| P/B Ratio | 2.87 | 4.77 | 6.8 | 3.75 | 1.66 | |
| PTB ratio | 2.87 | 4.77 | 6.8 | 3.75 | 1.66 | |
| EV to sales | 3.16 | 4.96 | 7.16 | 4.17 | 2.93 | |
| Enterprise value over EBITDA | 10.63 | 16.67 | 20.66 | 10.97 | 9.16 | |
| EV to operating cash flow | 43.79 | 34.78 | 24.24 | 10.28 | 12.53 | |
| EV to free cash flow | -25.27 | -353.95 | 44.75 | 16.37 | -73.08 | |
| Earnings yield | 0.06 | 0.04 | 0.03 | 0.06 | 0.07 | |
| Free cash flow yield | -0.04 | 0 | 0.02 | 0.06 | -0.01 | |
| Debt to equity | 0.44 | 0.48 | 0.35 | 0.26 | 0.11 | |
| Debt to assets | 0.26 | 0.27 | 0.21 | 0.17 | 0.09 | |
| Net debt to EBITDA | 0.94 | 1.11 | 0.55 | 0.32 | 0.1 | |
| Current ratio | 2.14 | 1.93 | 2.24 | 2.94 | 4.34 | |
| Interest coverage | 12.61 | 10.33 | 14.51 | 20.48 | 23.32 | |
| Income quality | 0.4 | 0.81 | 1.33 | 1.61 | 1.2 | |
| Dividend Yield | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 | |
| Payout ratio | 0.28 | 0.3 | 0.22 | 0.31 | 0.45 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.05 | 0.05 | 0.08 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0.05 | 0.06 | |
| Capex to operating cash flow | -2.73 | -1.1 | -0.46 | -0.37 | -1.17 | |
| Capex to revenue | -0.2 | -0.16 | -0.14 | -0.15 | -0.27 | |
| Capex to depreciation | -4.35 | -3.25 | -2.44 | -2.55 | -3.66 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | 0 | 0.01 | |
| Graham number | 9.39 | 10.99 | 14.87 | 17.4 | 16.58 | |
| ROIC | 0.12 | 0.12 | 0.16 | 0.19 | 0.1 | |
| Return on tangible assets | 0.1 | 0.1 | 0.13 | 0.15 | 0.09 | |
| Graham Net | 0.72 | 0.54 | 0.69 | 1.09 | 3.09 | |
| Working capital | 1.58B | 1.69B | 2.23B | 2.54B | 3.61B | |
| Tangible asset value | 2.7B | 3.1B | 3.74B | 4.24B | 6.01B | |
| Net current asset value | 1.27B | 1.34B | 1.67B | 1.83B | 3.07B | |
| Invested capital | 0.44 | 0.48 | 0.35 | 0.26 | 0.11 | |
| Average receivables | 1.5B | 1.94B | 2.19B | 2.14B | 2.18B | |
| Average payables | 158.4M | 230.49M | 331.83M | 359.74M | 349.16M | |
| Average inventory | 639.62M | 791.4M | 963.26M | 1.08B | 1.06B | |
| Days sales outstanding | 235.28 | 243.02 | 220.39 | 188.24 | 232.73 | |
| Days payables outstanding | 56.23 | 61.48 | 84.51 | 69.22 | 84.17 | |
| Days of inventory on hand | 206.18 | 200.18 | 225.94 | 234.71 | 229.7 | |
| Receivables turnover | 1.55 | 1.5 | 1.66 | 1.94 | 1.57 | |
| Payables turnover | 6.49 | 5.94 | 4.32 | 5.27 | 4.34 | |
| Inventory turnover | 1.77 | 1.82 | 1.62 | 1.56 | 1.59 | |
| ROE | 0.17 | 0.17 | 0.21 | 0.22 | 0.11 | |
| Capex per share | -0.96 | -0.91 | -0.9 | -1.09 | -1.64 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.58 | 1.51 | 1.1 | 1.15 | 1.2 | |
| Net income per share | 0.33 | 0.18 | 0.19 | 0.09 | 0.15 | |
| Operating cash flow per share | 0.33 | 0.18 | 0.19 | 0.4 | 0.34 | |
| Free cash flow per share | 0 | -0.61 | 0.04 | -0.01 | -0.02 | |
| Cash per share | 2.53 | 2.12 | 2.2 | 2.17 | 1.93 | |
| Book value per share | 10.41 | 10.64 | 10.45 | 10.2 | 10.34 | |
| Tangible book value per share | 9.98 | 10.16 | 9.98 | 9.69 | 9.81 | |
| Share holders equity per share | 10.41 | 10.64 | 10.45 | 10.2 | 10.34 | |
| Interest debt per share | 1.49 | 1.2 | 1.21 | 1.55 | 1.34 | |
| Market cap | 9.95B | 10.23B | 11.29B | 9.26B | 9.21B | |
| Enterprise value | 9.99B | 10.34B | 11.22B | 9.34B | 9.25B | |
| P/E ratio | 12.76 | 23.83 | 24.15 | 39.94 | 24.52 | |
| Price to sales ratio | 10.62 | 11.49 | 16.69 | 13.15 | 12.54 | |
| POCF ratio | 51.04 | 95.32 | 96.58 | 38.16 | 44.39 | |
| PFCF ratio | -6.43K | -28.57 | 517.86 | -1.15K | -766 | |
| P/B Ratio | 1.61 | 1.63 | 1.76 | 1.48 | 1.45 | |
| PTB ratio | 1.61 | 1.63 | 1.76 | 1.48 | 1.45 | |
| EV to sales | 10.67 | 11.62 | 16.58 | 13.27 | 12.59 | |
| Enterprise value over EBITDA | 43.37 | 75.09 | 72.34 | 95.18 | 58.17 | |
| EV to operating cash flow | 51.28 | 96.38 | 95.98 | 38.51 | 44.58 | |
| EV to free cash flow | -6.46K | -28.89 | 514.65 | -1.16K | -769.37 | |
| Earnings yield | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | -0.04 | 0 | 0 | 0 | |
| Debt to equity | 0.14 | 0.11 | 0.11 | 0.15 | 0.13 | |
| Debt to assets | 0.11 | 0.09 | 0.09 | 0.11 | 0.1 | |
| Net debt to EBITDA | 0.2 | 0.83 | -0.45 | 0.86 | 0.25 | |
| Current ratio | 4.32 | 4.34 | 4.65 | 4.31 | 3.71 | |
| Interest coverage | 24.75 | 17.87 | 23.02 | 5.13 | 12.82 | |
| Income quality | 1 | 1 | 1 | 4.19 | 2.21 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0.04 | 0.07 | 0.05 | 3.78 | 0.07 | |
| Sales general and administrative to revenue | 0.09 | -0.06 | 0.05 | -0.02 | 0.13 | |
| Research and developement to revenue | 0.07 | 0.12 | 0.09 | 0.1 | 0.12 | |
| Intangibles to total assets | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | |
| Capex to operating cash flow | -1.01 | -4.34 | -0.81 | -1.03 | -1.06 | |
| Capex to revenue | -0.21 | -0.52 | -0.14 | -0.36 | -0.3 | |
| Capex to depreciation | -2.52 | -5.97 | -1.33 | -3.52 | 1.55 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.77 | 6.59 | 6.7 | 4.66 | 5.97 | |
| ROIC | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Return on tangible assets | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Graham Net | 3.31 | 3.15 | 3.12 | 2.74 | 2.67 | |
| Working capital | 3.75B | 3.61B | 3.74B | 3.53B | 3.27B | |
| Tangible asset value | 5.93B | 6.01B | 6.11B | 5.94B | 6.01B | |
| Net current asset value | 3.14B | 3.07B | 3.14B | 2.84B | 2.81B | |
| Invested capital | 0.14 | 0.11 | 0.11 | 0.15 | 0.13 | |
| Average receivables | 2.25B | 2.29B | 2.24B | 2.13B | 2.09B | |
| Average payables | 351.91M | 377.53M | 391.57M | 385.16M | 393.09M | |
| Average inventory | 998.53M | 1.02B | 1.08B | 1.1B | 1.09B | |
| Days sales outstanding | 218.85 | 232.63 | 289.18 | 267.07 | 256.63 | |
| Days payables outstanding | 71.68 | 93.04 | 119.81 | 96.99 | 121.58 | |
| Days of inventory on hand | 191.85 | 253.91 | 335.29 | 285.09 | 317.67 | |
| Receivables turnover | 0.41 | 0.39 | 0.31 | 0.34 | 0.35 | |
| Payables turnover | 1.26 | 0.97 | 0.75 | 0.93 | 0.74 | |
| Inventory turnover | 0.47 | 0.35 | 0.27 | 0.32 | 0.28 | |
| ROE | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Capex per share | -0.33 | -0.79 | -0.16 | -0.41 | -0.36 |
300463.SZ Frequently Asked Questions
What is Maccura Biotechnology Co.Ltd stock symbol ?
Maccura Biotechnology Co.Ltd is a CN stock and trading under the symbol 300463.SZ
What is Maccura Biotechnology Co.Ltd stock quote today ?
Maccura Biotechnology Co.Ltd stock price is $11.7 today.
Is Maccura Biotechnology Co.Ltd stock public?
Yes, Maccura Biotechnology Co.Ltd is a publicly traded company.
Company Profile
- Volume Average 5.75M
- Market Capitalization 7.55B
- Employee 3.02K
- CEO Mr. Wu Mingjian
- Headquarters Chengdu,CN
- IPO Date 2015-05-28
-
Website
https://www.maccura.com 
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides SARS-COV-2(COVID-19) products that includes nucleic acid detection kit and other products; glucometers; POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR kit; and pathology products. The company was incorporated in 1994 and is based in Chengdu, China.
